CN110494449B - Alt-803与抗cd38抗体组合用于癌症治疗 - Google Patents

Alt-803与抗cd38抗体组合用于癌症治疗 Download PDF

Info

Publication number
CN110494449B
CN110494449B CN201880022531.7A CN201880022531A CN110494449B CN 110494449 B CN110494449 B CN 110494449B CN 201880022531 A CN201880022531 A CN 201880022531A CN 110494449 B CN110494449 B CN 110494449B
Authority
CN
China
Prior art keywords
antibody
cells
alt
cell
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880022531.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110494449A (zh
Inventor
N·什雷斯塔
刘白
彼得·罗德
黄兴忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alte Biotechnology
Original Assignee
Alte Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63678335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110494449(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alte Biotechnology filed Critical Alte Biotechnology
Publication of CN110494449A publication Critical patent/CN110494449A/zh
Application granted granted Critical
Publication of CN110494449B publication Critical patent/CN110494449B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880022531.7A 2017-03-31 2018-03-30 Alt-803与抗cd38抗体组合用于癌症治疗 Active CN110494449B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762480339P 2017-03-31 2017-03-31
US62/480,339 2017-03-31
US15/937,493 US20190048055A1 (en) 2017-03-31 2018-03-27 Alt-803 in combination with anti-cd38 antibody for cancer therapies
US15/937,493 2018-03-27
PCT/US2018/025366 WO2018183821A1 (en) 2017-03-31 2018-03-30 Alt-803 in combination with anti-cd38 antibody for cancer therapies

Publications (2)

Publication Number Publication Date
CN110494449A CN110494449A (zh) 2019-11-22
CN110494449B true CN110494449B (zh) 2024-03-26

Family

ID=63678335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880022531.7A Active CN110494449B (zh) 2017-03-31 2018-03-30 Alt-803与抗cd38抗体组合用于癌症治疗

Country Status (9)

Country Link
US (1) US20190048055A1 (https=)
EP (1) EP3601363B1 (https=)
JP (1) JP2020512361A (https=)
KR (1) KR102748188B1 (https=)
CN (1) CN110494449B (https=)
AU (1) AU2018243550B2 (https=)
CA (1) CA3058427C (https=)
TW (1) TW201841651A (https=)
WO (1) WO2018183821A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117986384A (zh) 2017-03-06 2024-05-07 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
JP2023502712A (ja) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
KR102692667B1 (ko) 2020-11-17 2024-08-06 고려대학교 산학협력단 면역치료요법의 효능, 예후, 또는 내성 예측을 위한 바이오마커, 및 면역치료요법의 효능 증진을 위한 표적으로서 tctp의 용도
CN113293191A (zh) * 2021-05-28 2021-08-24 山东大学齐鲁医院 Gfp转染肿瘤细胞的方法在检测肿瘤相关巨噬细胞吞噬功能中的应用
WO2023178253A2 (en) * 2022-03-18 2023-09-21 Igm Biosciences, Inc. Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2012040323A2 (en) * 2010-09-21 2012-03-29 Altor Bioscien Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
WO2013076183A1 (en) * 2011-11-25 2013-05-30 Roche Glycart Ag Combination therapy using anti - cd20 antibody and human il-15
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
CN104379169A (zh) * 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507A (en) 1851-11-11 petess
US222A (en) 1837-06-10 Truss for the retention and radical cure qe hernia
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7213961B2 (en) 2003-07-11 2007-05-08 Hubbell Incorporated Low voltage luminaire assembly
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA3151221C (en) * 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
AU2016333873A1 (en) * 2015-10-06 2018-05-17 The Wistar Institute Of Anatomy And Biology Methods and compositions for treatment of metastatic and refractory cancers and tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2012040323A2 (en) * 2010-09-21 2012-03-29 Altor Bioscien Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
CN103370339A (zh) * 2010-09-21 2013-10-23 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2013076183A1 (en) * 2011-11-25 2013-05-30 Roche Glycart Ag Combination therapy using anti - cd20 antibody and human il-15
CN104379169A (zh) * 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Novel Fusion of ALT-803 (IL-15 Superagonist) with an Antibody Demonstrates Antigen specific Antitumor Responses;Bai Liu等;《Journal of Biological Chemistry》;20161111;第291卷(第46期);第1-25页 *
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer;M. Felices等;《Gynecologic Oncology》;20170222;第145卷(第3期);第1-9页 *
Tumor burden reduction in an orthotopic non-muscle-invasive bladder cancer model using IL-15 analogue (ALT-803) targeting T regulatory cells.;Evan Gomes等;Journal of Clinical Oncology;第31卷(第6期);291-298 *
多发性骨髓瘤T细胞免疫治疗;刘海玲等;现代肿瘤医学;第24卷(第18期);2983-2988 *

Also Published As

Publication number Publication date
JP2020512361A (ja) 2020-04-23
TW201841651A (zh) 2018-12-01
CA3058427C (en) 2023-01-24
CA3058427A1 (en) 2018-10-04
EP3601363B1 (en) 2022-06-15
WO2018183821A1 (en) 2018-10-04
KR20190135036A (ko) 2019-12-05
EP3601363A1 (en) 2020-02-05
CN110494449A (zh) 2019-11-22
AU2018243550A1 (en) 2019-10-17
AU2018243550B2 (en) 2020-09-03
KR102748188B1 (ko) 2025-01-03
EP3601363A4 (en) 2020-07-29
US20190048055A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
CN110494449B (zh) Alt-803与抗cd38抗体组合用于癌症治疗
JP7561905B2 (ja) Ｉｌ－１５ベース分子及びその使用方法
JP6906653B2 (ja) 三重特異性結合タンパク質と使用方法
JP6609724B1 (ja) 抗ヒト４−１ｂｂ抗体およびその使用
EP3638700B1 (en) Proteinaceous heterodimer and use thereof
JP6170926B2 (ja) 癌胎児抗原関連細胞接着分子（ｃｅａｃａｍ）に対する抗体
JP7324565B2 (ja) Ｃｄ１２７に対する抗体
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
KR20180125435A (ko) 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
JP2019505564A (ja) 抗ｂｃｍａポリペプチド及びタンパク質
JP2020511950A (ja) 抗ｌｉｌｒｂ３抗体およびその使用の方法
JP2023502876A (ja) がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質
EP4346887A1 (en) C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
EP3322724B1 (en) Il-26 inhibitors
WO2022255248A1 (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240206

Address after: Florida, USA

Applicant after: Alte Biotechnology

Country or region after: U.S.A.

Address before: Florida, USA

Applicant before: ALTOR BIOSCIENCE Corp.

Country or region before: U.S.A.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant